Related references
Note: Only part of the references are listed.Relevance of the Immunoglobulin VH somatic mutation status in patients with chronic lymphocytic leukemia treated with fludarabine, cyclophosphamide, and rituximab (FCR) or related chemoimmunotherapy regimens
Katherine I. Lin et al.
BLOOD (2009)
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Mitch A. Phelps et al.
BLOOD (2009)
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
Constantine S. Tam et al.
BLOOD (2009)
Prognostic markers in chronic lymphocytic leukemia: A comprehensive review
Femke Van Bockstaele et al.
BLOOD REVIEWS (2009)
The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors
Davide Rossi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic Leukemia
Tait D. Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
F. Dicker et al.
LEUKEMIA (2009)
Monoclonal B-cell lymphocytosis: definitions and natural history
Tait Shanafelt et al.
LEUKEMIA & LYMPHOMA (2009)
The physician-patient relationship and quality of life: Lessons from chronic lymphocytic leukemia
Tait D. Shanafelt et al.
LEUKEMIA RESEARCH (2009)
Epidemiological study and comparison of MD Anderson Cancer Center and GIMENA. Adult Hematological Illness in patients with B-chronic lymphocytic leukemia
Ana Pilar Gonzalez Rodriguez et al.
MEDICINA CLINICA (2009)
Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia.: The impact of biological parameters in the response duration
Luca Laurenti et al.
ANNALS OF HEMATOLOGY (2008)
Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia
Laura Z. Rassenti et al.
BLOOD (2008)
Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia
Constantine S. Tam et al.
BLOOD (2008)
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz et al.
BLOOD (2008)
Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia:: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
Michael Hallek et al.
BLOOD (2008)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication
Francesc Bosch et al.
CLINICAL CANCER RESEARCH (2008)
Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression
Tait D. Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning
Mohamed L. Sorror et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Predictive value of blood and bone marrow flow Cytometry in B-Cell lymphoma classification: Comparative analysis of flow Cytometry and tissue biopsy in 252 patients
William G. Morice et al.
MAYO CLINIC PROCEEDINGS (2008)
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia
Peter Hillmen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of chronic lymphocytic leukemia and small lymphocytic lymphoma by absolute lymphocyte counts in 2,126 patients: 20 years of experience at the University of Texas MD Anderson Cancer Center
Apostolia M. Tsimberidou et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997
Michael R. Grever et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia
Neil E. Kay et al.
BLOOD (2007)
Methylprednisolone-rituximab is an effective salvage therapy for patients with relapsed chronic lymphocytic leukemia including those with unfavorable cytogenetic features
Deborah A. Bowen et al.
LEUKEMIA & LYMPHOMA (2007)
Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus
P. Dreger et al.
LEUKEMIA (2007)
Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia
William G. Wierda et al.
BLOOD (2007)
Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia
Tait D. Shanafelt et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia
BF Eichhorst et al.
BLOOD (2006)
Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy
JC Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Diagnostic criteria for monoclonal B-cell lymphocytosis
GE Marti et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes
IS Lossos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia
M Crespo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease
TJ Hamblin et al.
BLOOD (2002)
Genomic aberrations and survival in chronic lymphocytic leukemia.
H Döhner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2000)
Share Paper
